IFCAH
IFCAH 2027 Call for Projects is open!
IFCAH (International Fund Congenital Adrenal Hyperplasia) in partnership with ESPE (European Society for Paediatric Endocrinology) and ESE (European Society of Endocrinology) is delighted to announce its 2027 call for projects.
Deadline for a letter of intent application is 15 January 2027. Please make sure you receive a confirmation email after sending IFCAH the letter of intent. If this is not the case, please contact IFCAH at cfp@ifcah.org
Information about IFCAH and this call for projects is available on IFCAH’s website or by sending an email to cfp@ifcah.org. Specific forms for letters of intent can be obtained from cfp@ifcah.org
January 15, 2027: Letters of intention (LOI) due date
February 2027: LOI decision meeting
April 2027: Full application due date (for accepted LOIs)
June 2027: Audition of proposals
July 2027: Award notification
Background and further information
Background
IFCAH is a private fund, aimed to promote research on Congenital Adrenal Hyperplasia (CAH). In 2026, it launches its call for proposals, in association with ESPE and ESE. A total amount of €250.000 is associated to this program. Participation is open worldwide and will, if possible, include teams based in Europe.
Specific goals
Proposition of new therapeutic targets and protocols
- Gene and/or cellular therapy models.
- Development of physiological hormone replacement strategies, including circadian and ultradian cortisol replacement and optimized aldosterone replacement, treatment monitoring and dose adjustment
- Development of reliable emergency treatment devices.
Increasing knowledge on pathophysiology of CAH
The projects should be relevant to CAH. The projects could include research on adrenal development, differentiation and homeostasis. Research on adrenal tumours and cancer is excluded from this call.
Prevention, diagnosis and treatment of natural or iatrogenic complications
Impact on foetal development, growth, puberty, effects on metabolic and cardiovascular systems, male and female fertility, bone density, immunity, infection, neurocognition, and complications related to long-term hormone replacement.
Funding
Selected research projects will be supported up to EUR 150k (total). Funding period will have to start at the latest 6 months after notification of the award and will not exceed three years. Funds will have to be used for expenses directly linked to the project, including specific equipment, operating costs or salaries of co-workers (with the exception of salaries of senior permanent staff of academic and governmental agencies which are not eligible). Indirect costs or managements fees are not eligible and must be covered by another source. The funding is open to co-funding opportunities in order to support larger projects.
Eligibility
Applicants must hold an M.D., Ph.D., or equivalent academic degree and have a faculty position or equivalent at a college, university, medical school, or comparable institution. Only one project from a research team will be considered. Applications for the renewal of an IFCAH’s support are accepted but applications for a different project, from a team previously supported by IFCAH, will not be considered, up to the end of its former grant.
Selection procedures
The information given on LOI will enable the scientific board of IFCAH, ESPE and ESE to access the priority of the projects and to determine whether the proposed research merits a full application. Applicants will have to inform on project positioning versus international competitors. Full applications will be requested from selected LOIs and submitted to peer-review. Final selection will take place after an oral project’s presentation (on site in Paris or through video-conference) to the IFCAH, ESPE and ESE board.